Novel TNF antagonists for the treatment of rheumatoid arthritis

Bibliography

• Nikas SN, Voulgari PV, Alamanos Y, Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006;65:257-60
   PubMed Web of Science ®Google Scholar
• Gomez-Reino J, Group CLB. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29
   PubMed Web of Science ®Google Scholar
• Bombardieri S, Ruiz A, Fardellone P, Effectiveness of adalimumab in rheumatoid arthritis in patients with a history of TNF antagonists in clinical practice. Rheumatology 2007;46:1191-9
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8
   PubMed Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-69
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn's disease: exploring a new mechanism of action. BioDrugs 2008;22:331-7
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biologic therapies. BioDrugs 2008;22:315-29
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Brown D, Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl II):296
   Google Scholar
• Berthelot JM, De Bandt M, Goupille P, Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76:28-34
   PubMed Web of Science ®Google Scholar
• Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut 2009;58:608
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Choy EHS, Hazleman B, Smith M, Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002;41:1133-7
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, van Vollenhoven R, Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying anti-rheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11
   PubMed Web of Science ®Google Scholar
• Keystone E, van der Heijde D, Mason D, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29
   PubMed Web of Science ®Google Scholar
• Emery P, Furst DE, Keystone EC, Certolizumab pegol remains equally efficacious in the treatment of rheumatoid arthritis over a range of background methotrexate regimens (10-30 mg/wk): Analysis of the RAPID1 trial. Abstract #THU-0139, EULAR 2008
   Google Scholar
• Smolen JS, Landewe RBM, Mease PJ, Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. Ann Rheum Dis 2009;68:797-804
   PubMed Web of Science ®Google Scholar
• Inman RD, Davis JC, van der Heijde D, Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86
   PubMed Web of Science ®Google Scholar
• Shealy D, Cai A, Lacy E, Characterization of golimumab (CNTO148), a novel fully human monoclonal antibody specific for TNFalpha (abstract). Ann Rheum Dis 2007;66(Suppl II):151
   PubMedGoogle Scholar
• Zhou H, Jang H, Fleischmann RM, Pharmacokinetics and safety of golimumab, a fully human anti-TNFalpha monoclonal antibody, in subjects with Rheumatoid Arthritis. J Clin Pharmacol 2007;47:383-96
   PubMed Web of Science ®Google Scholar
• Kay J, Matteson EL, Dasgupta B, Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Arthritis Rheum 2008;58:964-75
   PubMed Web of Science ®Google Scholar
• Keystone EC, Genovese MC, Klareskog L, Golimumab, a human antibody to TNF-alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate: the GO-FORWARD study. Ann Rheum Dis 2009;68:789-96
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann RM, Moreland LW, Golimumab, a Human Anti-Tumor Necrosis Factor alpha Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naïve Patients with Active Rheumatoid Arthritis. Arthritis Rheum 2009;60:2272-83
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, van der Heijde D, Golimumab and Radiographic Progression in Rheumatoid Arthritis: Results of GO-BEFORE and GO-FORWARD Studies. Abstract #640, ACR 2009
   Google Scholar
• Smolen JS, Kay J, Doyle MK, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled phase III trial. Lancet 2009;374:210-21
   PubMed Web of Science ®Google Scholar
• Elliott M, Maini R, Feldmann M, Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial. Ann Intern Med 1999;130:478-86
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93
   PubMed Web of Science ®Google Scholar
• van de Putte LB, Atkins C, Malaise M, Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthrits Rheuum 1998;41:1552-63
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-center, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker J-C, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2006;54:2793-806
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Lunt M, Watson KD, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:13-20
   PubMed Web of Science ®Google Scholar
• Finckh A, Ciure A, Brulhart L, B Cell depletion may be More effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis Patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23
   PubMed Web of Science ®Google Scholar